The many challenges encountered by the use of biologics for therapeutic purposes in areas including oncology clearly indicate a requirement for de novo development of novel therapeutic proteins. Protein/target hunter is a platform utilizing AI simulation-coupled with phage display technology for rapid development of novel proteins.
For example, for tumor immunotherapy, tumor antigen escape and the harsh tumor microenvironment (TME) present challenges that would require the development of novel tumor-targeting molecules such as single chain variable fragments (scFv) and nanobodies, or novel engineered protein modulators. Therefore, in collaboration with TMU BIOMED Gloria, GenomeFrontier Therapeutics utilized this platform to successfully develop a number of therapeutic protein candidates for specific targeting to tumor antigens and/or for modulating the TME. A brief schematic diagram illustrating how Protein/Target Hunter achieves this is shown (Figure 1):
Figure 1. Protein/ Target Hunter. After AI prediction and machine learning, a set of repertoire primers with high diversity are synthesized and annealed to human single-strand phagemid DNA for generation of phage-displayed protein/peptide library. Following several rounds of biopanning, the selected candidate(s) are genetically engineered into therapeutic target cells for gene-modified cell therapy.